×
收藏-健康|会(x)员访问记?/h3>
| |页标题Q? | |
×
注册健康|用?/h3>
| ??名：(x) | ||
|---|---|---|
| ?p?人：(x) | ?nbsp; 别：(x) | |
| ?nbsp; 码：(x) | ||
| 重复密码Q?/th> | ||
| ?sh)子邮箱Q?/th> | ||
| 固定?sh)话Q?/th> | ||
| ?nbsp; 真：(x) | ||
| ?nbsp; 机：(x) | ||
| 单位名称Q?/th> | ||
| 通信地址Q?/th> | ||
| 首选栏目：(x) | ||
| 我已l认真阅dƈ同意《健L(fng)服务条款?/a> | ||
| 定注册 | ||
2023q全球CRO排名TOP10
作者：(x)xuezhe 来源Q互联网 点击敎ͼ(x)0 更新旉Q?024/4/12 14:57:45
相关q接
|氏C代抗体疗法“crovalimab”获FDA批准上市
?ji)洲药业投?200万美元在日本CRO服务q_
The industrial chain effect of macrolide APIs is prominent
Reasons for the sales growth of macrolides in Guo Bang Pharmaceutical in the first half of 2023
The project of Angel Yeast Binzhou Company with an annual output of 40,000 tons of new yeast products (microbial protein) has been completed put into production.
Analysis of 70 macrocyclic drugs approved by the FDA
_?022q净利润同比增长q三?/a>
|氏C5补体抑制剂Crovalimab全球3期试验结果积?/a>
?ji)洲药业投?200万美元在日本CRO服务q_
The industrial chain effect of macrolide APIs is prominent
Reasons for the sales growth of macrolides in Guo Bang Pharmaceutical in the first half of 2023
The project of Angel Yeast Binzhou Company with an annual output of 40,000 tons of new yeast products (microbial protein) has been completed put into production.
Analysis of 70 macrocyclic drugs approved by the FDA
_?022q净利润同比增长q三?/a>
|氏C5补体抑制剂Crovalimab全球3期试验结果积?/a>